BOCA RATON, Fla., Nov. 19, 2015 /PRNewswire/ -- IM HealthScience®, innovators of IBgard®, a medical food using a novel approach in managing irritable bowel syndrome (IBS), announced today results of a nationwide survey conducted among 202 U.S. gastroenterologists by AlphaImpactRx using its ProVoice survey methodology.
The survey revealed that 83 percent of physicians are now recommending peppermint oil for their IBS patients and IBgard® was by far the market leader with 64 percent of physician recommendations. The next product on the list was a distant second with about 9 percent of physician recommendations. (Please see survey results at top of press release).
"These results underscore the growing acceptance among gastroenterologists of using peppermint oil for IBS, and more importantly the proven efficacy and safety of IBgard®," said Michael Epstein, M.D., a leading gastroenterologist and Chief Medical Advisor, of IM HealthScience, LLC®. Over 10,000 healthcare practitioners, including 3,000 gastroenterologists, are estimated to have already used IBgard® for their patients.
AlphaImpactRx is the leading provider of primary research-based insights, analytics and solutions to biopharmaceutical, consumer health and medical device companies. Through the combination of its consulting expertise, innovative technology, proprietary physician panels and syndicated data assets, AlphaImpactRx provides market research to help its global healthcare clients make informed and timely business decisions to develop and market their products. For more information, please visit www.alphaimpactrx.com.
About ProVoice Survey
ProVoice has the largest sample size of any professional healthcare survey in the U.S., with nearly 60,000 respondents across physicians, nurse practitioners, physician assistants, optometrists, dentists and hygienists, measuring recommendations across more than 120 over-the-counter categories. Manufacturers use ProVoice for claim substantiation, promotion measurement and HCP targeting.
AlphaImpactRx fielded a U.S. survey among 202 U.S. gastroenterologists between October/November 2015 for IM HealthScience®. The ProVoice survey methodology validated the claim at a 99 percent confidence level that "IBgard is the #1 gastroenterologist-recommended peppermint oil for patients with IBS."
About Irritable Bowel Syndrome
One in six Americans experience Irritable Bowel Syndrome (IBS), a frustrating, underdiagnosed and undertreated condition characterized by abdominal pain associated with alteration in stool frequency and/or form. Bloating is also a common symptom experienced by patients with IBS. Doctors are not sure what causes IBS and it is likely that there are numerous etiologies that manifest as a similar syndrome of symptoms. There is currently no cure for IBS and management options are limited.
IBgard® is a medical food containing L-menthol, the principal component in peppermint oil, which has been shown to have significant impact on the management of IBS symptoms. In multiple clinical studies, including one trial on IBgard, peppermint oil has been shown to provide relief from IBS symptoms. Peppermint oil can help normalize the digestion of food and absorption of nutrients, which have been compromised by IBS. Peppermint oil has also been shown to normalize intestinal transit time. With its patented SST® technology, pioneered by IM HealthScience®, IBgard® capsules release Ultramen®, an ultra-purified peppermint oil, in the small intestine.
While IBgard® does not require a prescription, as a medical food, it must be used under medical supervision. The usual adult dose of IBgard® is 1-2 capsules as needed, up to three times a day, not to exceed 8 capsules per day.
IBgard® is now accessible to consumers in the digestive aisle at most CVS/pharmacy and Walgreens stores nationwide. For more information, visit www.IBgard.com to learn more about IBgard®.
About IM HealthScience®
IM HealthScience® is a privately held company based in Boca Raton, Florida, that developed IBgard®. It was founded in 2010 by a team of highly experienced pharmaceutical research and development and management executives. The company is dedicated to developing products to address gastrointestinal issues where there is a high, unmet need, including Irritable Bowel Syndrome (IBS), Functional Dyspepsia, Ulcerative Colitis, and Crohn's Disease. The IM HealthScience® advantage comes from developing products based on its patented, targeted-delivery technologies called Site Specific Targeting (SST®).
SOURCE IM HealthScience